Your browser doesn't support javascript.
loading
Cancer-related fatigue trajectories up to 5 years after curative treatment for oesophageal cancer.
Cheng, Zhao; Johar, Asif; Nilsson, Magnus; Schandl, Anna; Lagergren, Pernilla.
Affiliation
  • Cheng Z; Surgical Care Science, Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Johar A; Surgical Care Science, Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Nilsson M; Division of Surgery, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden.
  • Schandl A; Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden.
  • Lagergren P; Surgical Care Science, Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Br J Cancer ; 130(4): 628-637, 2024 03.
Article in En | MEDLINE | ID: mdl-38135716
ABSTRACT

BACKGROUND:

Whether cancer-related fatigue develops differently after curative-intended oesophageal cancer treatment and the related modifiable factors are unclear.

METHODS:

This population-based and longitudinal cohort included 409 oesophageal cancer patients who underwent curative oesophagectomy in 2013-2020 in Sweden. The main outcome was cancer-related fatigue trajectories with measurements at 1, 1.5, 2, 2.5, 3, 4 and 5 years postoperatively by validated EORTC QLQ-FA12 questionnaire, and analysed using growth mixture models. Weighted logistic regressions provided odds ratios (OR) with 95% confidence intervals (95% CI) for underlying sociodemographic, clinical, and patient-reported outcome factors in relation to the identified trajectories.

RESULTS:

Two distinct overall cancer-related fatigue trajectories were identified low level of persistent fatigue and high level of increasing fatigue, with 64% and 36% of patients, respectively. The odds of having high level of fatigue trajectory were increased by Charlson comorbidity index (≥ 2 versus 0 OR = 2.52, 95% CI 1.07-5.94), pathological tumour Stage (III-IV versus 0-I OR = 2.52, 95% CI 1.33-4.77), anxiety (OR = 7.58, 95% CI 2.20-26.17), depression (OR = 15.90, 95% CI 4.44-56.93) and pain (continuous score OR = 1.02, 95% CI 1.01-1.04).

CONCLUSIONS:

Long-term trajectories with high level of increasing cancer-related fatigue and the associated modifiable factors were identified after oesophageal cancer treatment. The results may facilitate early identification and targeted intervention for such high-risk patients.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Esophageal Neoplasms Limits: Humans Country/Region as subject: Europa Language: En Journal: Br J Cancer Year: 2024 Document type: Article Affiliation country: Suecia

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Esophageal Neoplasms Limits: Humans Country/Region as subject: Europa Language: En Journal: Br J Cancer Year: 2024 Document type: Article Affiliation country: Suecia